Source: http://docplayer.net/1225516-Guidance-for-industry.html
Timestamp: 2017-07-22 13:34:20
Document Index: 92801038

Matched Legal Cases: ['art 11', 'art 11', 'art 11', 'art 11', 'art13', 'art 11', 'art 312', 'art 812', 'art 170', 'ART 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'ART 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'ART 11', 'art 11', 'ART 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'art 11', 'ART 11', 'ART 11', 'art 11', 'art 11', 'art 11']

1 Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) September 2013 Procedural2 Guidance for Industry Electronic Source Data in Clinical Investigations Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration New Hampshire Ave., Bldg. 51, rm Silver Spring, MD Tel: ; Fax: ; and/or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD Tel: or and/or Office of Communication, Education and Radiological Programs Division of Small Manufacturers Assistance, Bldg. 66, rm Center for Devices and Radiological Health Food and Drug Administration New Hampshire Ave., Silver Spring, MD Fax: (Tel) Manufacturers Assistance: or U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) September 2013 Procedural3 Guidance for Industry Electronic Source Data in Clinical Investigations For questions regarding this guidance please contact: CDER: / or / CBER: / CDRH: / U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) September 2013 Procedural4 TABLE OF CONTENTS I. INTRODUCTION... 1 II. III. IV. BACKGROUND... 2 ELECTRONIC SOURCE DATA... 3 A. Data Capture Electronic Source Data Origination Source Data Capture Data Element Identifiers Modifications and Corrections Use of Electronic Prompts, Flags, and Data Quality Checks in the ecrf... 6 B. Data Review Clinical investigator(s) Modifications and Corrections During Clinical Investigator(s) Review of the ecrf... 7 C. Retention of Records by Clinical Investigator(s)... 7 D. Data Access... 8 USE AND DESCRIPTION OF COMPUTERIZED SYSTEMS IN CLINICAL INVESTIGATIONS... 8 REFERENCES... 9 GLOSSARY OF TERMS... 105 Guidance for Industry 1 Electronic Source Data in Clinical Investigations This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance. I. INTRODUCTION This guidance provides recommendations to sponsors, Contract Research Organizations (CROs), clinical investigators, and others involved in the capture, review, and retention of electronic source data in FDA-regulated clinical investigations. 2 In an effort to streamline and modernize clinical investigations this guidance promotes capturing source data in electronic form, and it is intended to assist in ensuring the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission. This guidance addresses source data in clinical investigations used to fill the predefined fields in an electronic case report form (ecrf), according to the protocol. The guidance discusses the following topics related to electronic source data: Identification and specification of authorized source data originators Creation of data element identifiers to facilitate examination of the audit trail by sponsors, FDA, and other authorized parties Ways to capture source data into the ecrf using either manual or electronic methods Clinical investigator(s) responsibilities with respect to reviewing and retaining electronic data Use and description of computerized systems in clinical investigations This guidance is intended to be used together with the FDA guidance for industry on Computerized Systems Used in Clinical Investigations (the computerized systems guidance), 3 1 This guidance has been prepared by the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, and the Center for Devices and Radiological Health at the Food and Drug Administration. 2 See definitions in 21 CFR 50.3 and We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at the Vaccines, Blood, and Biologics guidance Web page at or the Medical Devices guidance Web page at 16 and FDA regulation on Electronic Records and Electronic Signatures. 4 Electronic structures and standards related to electronic submissions are out of scope for this guidance. FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. BACKGROUND With the use of computerized systems for capturing clinical investigation data, it is common to find at least some source data recorded electronically. Common examples include, but are not limited to clinical data initially recorded in electronic health records maintained by healthcare providers and institutions, electronic laboratory reports, digital medical images from devices, and electronic diaries completed by study subjects. FDA regulations define an electronic record as any combination of text, graphics, data, audio, pictorial, or other information represented in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system. 5 An ecrf is an example of an electronic record. The ecrf is an auditable electronic record of information that generally is reported to the sponsor on each trial subject, according to a clinical investigation protocol. The ecrf enables clinical investigation data to be systematically captured, reviewed, managed, stored, analyzed, and reported. Source data includes all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical investigation used for reconstructing and evaluating the investigation. 6 Access to source data is critical to the review and inspections of clinical investigations. The review of source data by both the FDA and sponsor is important to ensure adequate protection of the rights, welfare, and safety of human subjects and the quality and integrity of the clinical investigation data. Source data should be attributable, legible, contemporaneous, original, and accurate (ALCOA) and must meet the regulatory requirements for recordkeeping. 7 Capturing source data electronically and transmitting it to the ecrf should: 4 See 21 CFR part CFR 11.3(b)(6). 6 In 21 CFR (b), reference is made to records that are part of case histories as supporting data ; the ICH guidance for industry E6 Good Clinical Practice: Consolidated Guidance (the ICH E6 guidance) (available at or uses the term source data/documents. For the purpose of this guidance, these terms describe the same information and have been used interchangeably. 7 For the principal record keeping requirements for clinical investigators and sponsors developing drugs and biologics, see 21 CFR , , , and For medical devices, see 21 CFR and7 III. Eliminate unnecessary duplication of data Reduce the possibility for transcription errors Encourage entering source data during a subject s visit, where appropriate Eliminate transcription of source data prior to entry into an ecrf Facilitate remote monitoring of data Promote real-time access for data review Facilitate the collection of accurate and complete data ELECTRONIC SOURCE DATA Electronic source data are data initially recorded in electronic format. They can include information in original records and certified copies of original records of clinical findings, observations, or other activities captured prior to or during a clinical investigation used for reconstructing and evaluating the investigation. A. Data Capture 1. Electronic Source Data Origination A data element in an ecrf represents the smallest unit of observation captured for a subject in a clinical investigation. Examples of data elements include race, white blood cell count, pain severity measurement, or other clinical observations made and documented during a study. Each data element is associated with an authorized data originator. Examples of data originators include, but are not limited to: Clinical investigator(s) and delegated clinical study staff Clinical investigation subjects or their legally authorized representatives Consulting services (e.g., a radiologist reporting on a computed tomography (CT) scan) Medical devices (e.g., electrocardiograph (ECG) machine and other medical instruments such as a blood pressure machine) Electronic health records (EHRs) Automated laboratory reporting systems (e.g., from central laboratories) Other technology A list of all authorized data originators (i.e., persons, systems, devices, and instruments) should be developed and maintained by the sponsor and made available at each clinical site. In the case of electronic, patient-reported outcome measures, the subject (e.g., unique subject identifier) should be listed as the originator. When identification of data originators relies on identification (log-on) codes and unique passwords, controls must be employed to ensure the security and integrity of the authorized user 38 names and passwords. 8 When electronic thumbprints or other biometric identifiers are used in place of an electronic log-on/password, controls should be designed to ensure that they cannot be used by anyone other than their original owner. When a system, device, or instrument automatically populates a data element field in the ecrf, a data element identifier (see section III.A.3) should be created that automatically identifies the particular system, device, or instrument (e.g., name and type) as the originator of the data element. For example, if an ECG machine automatically transmits to the ecrf, a data element identifier should be generated that identifies the ECG machine as the originator. 2. Source Data Capture Data can be entered into the ecrf either manually or electronically as described below. a. Direct Entry of Data Into the ecrf Many data elements (e.g., blood pressure, weight, temperature, pill count, resolution of a symptom or sign) in a clinical investigation can be obtained at a study visit and can be entered directly into the ecrf by an authorized data originator. This direct entry of data can eliminate errors by not using a paper transcription step before entry into the ecrf. For these data elements, the ecrf is the source. If a paper transcription step is used, then the paper documentation should be retained and made available for FDA inspection (see section III.A.2.c). When pertinent supportive information is available, FDA could request other documents during an inspection to corroborate a direct entry of source data elements into the ecrf by an authorized data originator. For example, at an initial visit, a clinical investigator might ask a subject about underlying illnesses, and proceed to enter the illness(es) in an ecrf. During an FDA inspection, a record may be requested for evidence of testing or the use of medications to corroborate a diagnosis. Typically, images (e.g., CT scans) are not included as data elements in an ecrf, but rather the clinical interpretation of the image is included as a predefined data field. When an image (e.g., a CT scan) is sent to a central reading center for clinical interpretation and the radiologist is authorized to enter data directly into the ecrf, then the radiologist s assessment (e.g., normal) is the data element as predefined in the ecrf, the radiologist is the data originator and the CT scan is the pertinent clinical record. However, when the radiologist sends a report to a clinical investigator(s) who transcribes the data into the ecrf, the clinical investigator(s) is the originator and the source is the radiologist s report. b. Automatic Transmission of Data From Devices or Instruments Directly to the ecrf When a device or instrument is the data originator (e.g., blood pressure monitoring device or glucometer) and data are automatically transmitted directly to the ecrf, the ecrf is the source. If a process is used by which the device or instrument transmits data automatically to, for 8 21 CFR (a); see also the computerized systems guidance. 49 example, an electronic health record system or to a service provider s database, then the EHR or the service provider s database is the source. c. Transcription of Data From Paper or Electronic Sources to the ecrf Data elements can be transcribed into the ecrf from paper or electronic source documents. The authorized person transcribing the data from the source documents is regarded as the data originator. For these data elements, the electronic or paper documents from which the data elements are transcribed are the source. These data must be maintained by the clinical investigator(s) and available to an FDA inspector if requested (e.g., an original or certified copy of a laboratory report, instrument printout, progress notes of the physician, the study subject s hospital chart(s), nurses notes). 9 d. Direct Transmission of Data From the Electronic Health Record to the ecrf Data elements originating in an EHR can be transmitted directly into the ecrf automatically. Unlike a direct transmission to an ecrf from instruments or medical devices, EHRs can use intervening processes (e.g., algorithms for the selection of the appropriate data elements). For this reason the EHR is the source, and the pertinent data for the subjects in the clinical study should be made available for review during an FDA inspection. The ability of sponsors and/or monitors to access health records of study subjects in clinical information systems relevant to the clinical investigation should not differ from their ability to access health records recorded on paper. e. Transmission of Data From Patient-Reported Outcome (PRO) Instruments to the ecrf When a PRO instrument is used by a subject to transmit data elements directly to the ecrf, the subject is the data originator and the ecrf is the source. If a process is used by which the subject uses the instrument to transmit data to a technology service provider database, the service provider database is the source. 3. Data Element Identifiers The ecrf should include the capability to record who entered or generated the data and when it was entered or generated. Changes to the data must not obscure the original entry, and must record who made the change, when, and why. 10 Data element identifiers should be attached to each data element as it is entered or transmitted by the originator into the ecrf. Data element identifiers should contain the following: Originators of the data element (including those data elements entered manually (e.g., by the clinical investigator(s)) and automatically (e.g., EHR, device, or instrument)) 9 21 CFR (b) and (a)(3) CFR 11.10(e). 510 Date and time the data element was entered into the ecrf (the audit trail begins at the time the data are transmitted to the ecrf) Clinical investigation subjects to which the data element belongs These data element identifiers will allow sponsors, FDA, and other authorized parties to examine the audit trail of the ecrf data (and this audit trail should be readily available in a human readable form). In addition, they provide information that will allow FDA to reconstruct and evaluate the clinical investigation. Although it is not necessary to automatically display the data element identifiers wherever data elements appear in the ecrf, the ecrf system should include a functionality that enables FDA to reveal or access the identifiers related to each data element. 4. Modifications and Corrections Only a clinical investigator(s) or delegated clinical study staff should perform modifications or corrections to ecrf data. Modified and/or corrected data elements must have data element identifiers that reflect the date, time, originator and reason for the change, and must not obscure previous entries. 11 A field should be provided allowing originators to describe the reason for the change (e.g., transcription error). Automatic transmissions should have traceability and controls via the audit trail to reflect the reason for the change. 5. Use of Electronic Prompts, Flags, and Data Quality Checks in the ecrf We encourage the use of electronic prompts, flags, and data quality checks in the ecrf to minimize errors and omissions during data entry. 12 Prompts can be designed to alert the data originator to missing data, inconsistencies, inadmissible values (e.g., date out of range), and to request additional data where appropriate (e.g., by prompting a clinical investigator(s) to complete an adverse event report form triggered by a critical laboratory result). Clinical investigator(s) should have the ability to enter comments about issues associated with the data. Sponsors should describe (e.g., in a data management plan) the electronic prompts, flags, and data quality checks that are designed to address, for example, data inconsistencies, missing data, and entries out of range. B. Data Review 1. Clinical investigator(s) The clinical investigator is the individual who conducts a clinical investigation (i.e., under whose immediate direction the test article or investigational product is administered or dispensed to, or used involving, a subject), or in the event of an investigation conducted by a team of individuals, is the responsible leader of that team CFR 11.10(e). 12 See the computerized systems guidance. 13 See definitions in 21 CFR 312.3(b) and 812.3(i). 611 a. Clinical Investigator(s) Review and Electronic Signature To comply with the requirement to maintain accurate case histories 14 clinical investigator(s) should review and electronically sign the completed ecrf for each subject before the data are archived or submitted to FDA. 15 Use of electronic signatures must comply with part 11 (21 CFR part 11). b. Data Exempt From Investigator Review Under certain circumstances, the clinical investigator(s) can be masked to specific data in the ecrf. For example, in a blinded study of an osmotic diuretic, the urine osmolality should not be revealed to the clinical investigator(s). In some studies specific administrative data (e.g., code lists) might be exempt from review. Data exempt from review should be listed (e.g., in a data management plan). 2. Modifications and Corrections During Clinical Investigator(s) Review of the ecrf To comply with the requirement to maintain accurate case histories, 16 data elements might call for modification or correction during clinical investigator(s) review. Either the clinical investigator(s) or an originator can enter the revised data element. Modified and/or corrected data elements must have data element identifiers that reflect the date, time, originator, and reason for the change, and must not obscure previous entries. 17 If changes are made to the ecrf after the clinical investigator(s) has already signed, the changes should be reviewed and electronically signed by the clinical investigator(s). C. Retention of Records by Clinical Investigator(s) The clinical investigator(s) should retain control of the records (i.e., completed and signed ecrf or certified copy of the ecrf). The clinical investigator(s) should provide FDA inspectors with access to the records that serve as the electronic source data. When data elements are transcribed from paper sources into an ecrf, the clinical investigator(s) must also retain the paper sources, or certified copies, for FDA review. 18 Other records (electronic and paper) required to corroborate data in the ecrf (see section III.A.2.a) may also be requested by FDA during an inspection CFR (b) and (a)(3). 15 See the ICH E6 guidance; see also 21 CFR part 11, subpart C CFR (b) and (a)(3) CFR 11.10(e) CFR (b) and (a)(3). 19 Ibid. 712 1 2 D. Data Access 3 Sponsors, CROs, data safety monitoring boards, and other authorized personnel can view the 4 data elements in the ecrf before and after the clinical investigator(s) has electronically signed 5 the completed ecrf. We encourage viewing the data to allow early detection of study-related 6 problems (e.g., safety concerns, protocol deviations) and problems with conducting the study 7 (e.g., missing data, data discrepancies). 8 9 The sponsor should have a list (e.g., in a data management plan) of the individuals with 10 authorized access to the ecrf. Only those individuals who have documented training and 11 authorization should have access to the ecrf data. 20 Individuals with authorized access should 12 be assigned their own identification (log-on) codes and passwords. 21 Log-on access should be 13 disabled if the individual discontinues involvement during the study IV. USE AND DESCRIPTION OF COMPUTERIZED SYSTEMS IN CLINICAL 16 INVESTIGATIONS Adequate controls should be in place to ensure confidence in the reliability, quality, and integrity 19 of the electronic source data. The determination of whether a computer system used in a clinical 20 investigation is suitable for its intended purpose might not be under the control of the clinical 21 investigator(s) or sponsor (e.g., EHRs). The performance standards for these computer systems 22 may be regulated by other authorities 22 and under the control of, for example, healthcare 23 providers or institutions. FDA does not intend to assess the compliance of EHRs with part Sponsors should include (e.g., in the protocol, data management plan, or investigational plan) 26 information about the intended use of computerized systems used during a clinical investigation, 27 a description of the security measures employed to protect the data, and a description or diagram 28 of the electronic data flow See 21 CFR 11.10(i). 21 See 21 CFR part 11.10(d). 22 See 45 CFR part13 32 REFERENCES Code of Federal Regulations, Title 21 part 11: Electronic Records; Electronic Signatures Code of Federal Regulations, Title : Definitions Code of Federal Regulations, Title 21 part 312: Investigational New Drug Application Code of Federal Regulations, Title 21 part 812: Investigational Device Exemptions Code of Federal Regulations, Title 45 part 170: Health Information Technology Standards, 43 Implementation Specifications, and Certification Criteria and Certification Programs for 44 Health Information Technology Food and Drug Administration, guidance for industry on Computerized Systems Used in 47 Clinical Investigations, available at htm Food and Drug Administration, ICH guidance for industry E6 Good Clinical Practice: 52 Consolidated Guidance, available at htm14 GLOSSARY OF TERMS 61 The following is a list of terms and definitions used in this guidance: Audit Trail: A process that captures details such as additions, deletions, or alterations of 64 information in an electronic record without obscuring the original record. An audit trail 65 facilitates the reconstruction of the course of such details relating to the electronic record Certified Copy: A copy (paper or electronic) of original information that has been verified, as 68 indicated by a dated signature, as an exact copy, having all of the same attributes and information 69 as the original Clinical Investigator: Investigator means an individual who actually conducts a clinical 72 investigation (i.e., under whose immediate direction the drug is administered or dispensed to a 73 subject). In the event an investigation is conducted by a team of individuals, the investigator is 74 the responsible leader of the team. Subinvestigator includes any other individual member of 75 that team (21 CFR 312.3) Computerized System: Includes computer hardware, software, and associated documents (e.g., 78 user manual) that create, modify, maintain, archive, retrieve, or transmit in digital form 79 information related to the conduct of a clinical investigation Data Element: A single observation associated with a subject in a clinical study. Examples 82 include birth date, white blood cell count, pain severity measure, and other clinical observations 83 made and documented during a study Data Element Identifier: Information associated with a data element that includes the origin of 86 the data element, the date and time of entry, and the identification number of the study subject to 87 whom the data element applies. Once set by the computerized system, this value should not be 88 alterable in any way Data Originator: Each data element is associated with an origination type that identifies the 91 source of its capture in the ecrf. This could be a person, a computer system, a device, or an 92 instrument that is authorized to enter, change, or transmit data elements into the ecrf (also 93 sometimes known as an author) Direct Entry: Initial recording of data into an electronic record. Examples are the keying by an 96 individual of original observations into a system, or automatic recording by a system of the 97 output of a balance that measures a subject s body weight Electronic Case Report Form (ecrf): An auditable electronic record of information that 100 generally is reported to the sponsor on each trial subject, according to a clinical investigation 101 protocol. The ecrf enables clinical investigation data to be systematically captured, reviewed, 102 managed, stored, analyzed, and reported15 104 Electronic Health Record (EHR): An electronic record for healthcare providers to create, 105 import, store, and use clinical information for patient care, according to nationally recognized 106 interoperability standards. NOTE: The EHR has the following distinguishing features: able to 107 be obtained from multiple sources, shareable, interoperable, accessible to authorized parties Electronic Record: Any combination of text, graphics, data, audio, pictorial, or other 110 information representation in digital form that is created, modified, maintained, archived, 111 retrieved, or distributed by a computer system (21 CFR 11.3(b)(6)) Electronic Signature: A computer data compilation of any symbol or series of symbols 114 executed, adopted, or authorized by an individual to be the legally binding equivalent of the 115 individual's handwritten signature (21 CFR 11.3(b)(7)) Electronic Source Data: Electronic source data are data initially recorded in electronic format Source Data: All information in original records and certified copies of original records of 120 clinical findings, observations, or other activities (in a clinical investigation) used for the 121 reconstruction and evaluation of the trial. Source data are contained in source documents 122 (original records or certified copies) Transmit: To transfer data within or among clinical study sites, contract research organizations, 125 data management centers, sponsors, or to FDA; to transfer data, usually electronically. 11 Similar documents
Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft More information FDA Regulation of Electronic Source Data in Clinical Investigations
FDA Regulation of Electronic Source Data in Clinical Investigations Q1 Productions Second Annual Innovations in Clinical Data Management Conference, Arlington, VA Mahnu Davar Presented on Oct. 28, 2014 More information Use of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding More information Guidance for Industry Computerized Systems Used in Clinical Investigations
Guidance for Industry Computerized Systems Used in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration (FDA) Office of the Commissioner (OC) May 2007 Guidance More information Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS
Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS U.S. Department of Health and Human Services Food and Drug Administration Center for Biologic Evaluation and Research (CBER) Center for More information Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and More information Final Guidance on Electronic Source Data in Clinical Investigations Promoting esource Data Capture
Final Guidance on Electronic Source Data in Clinical Investigations Promoting esource Data Capture CDER Leonard Sacks, Office of Medical Policy Ron Fitzmartin, Office of Strategic Programs Jonathan Helfgott, More information Data Management DM STANDARD OPERATING PROCEDURE FOR Data Management
Data Management DM 401.00 STANDARD OPERATING PROCEDURE FOR Data Management Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell, MD, FACP More information Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special More information Implementation of 21CFR11 Features in Micromeritics Software Software ID
Implementation of 21CFR11 Features in Micromeritics Software Software ID PART 11 ELECTRONIC RECORDS; ELECTRONIC SIGNATURES Subpart A General Provisions Sec. 11.1 Scope. 11.2 Implementation. 11.3 Definitions. More information Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug More information Guidance for Industry
Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this More information GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS
European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS More information Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps
Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Time Stamps Draft Guidance This guidance document is being distributed for comment purposes only. Comments and suggestions More information Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB
Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration More information Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center More information Self-Assessment of eresearch Compliance with 21 CFR Part 11, Electronic Record; Electronic Signatures
Self-Assessment of eresearch Compliance with 21 CFR Part 11, Electronic Record; Electronic Signatures Subpart A General Provisions Sec. 11.1 Scope. (a) The regulations in this part set forth the criteria More information Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials
09 June 2010 EMA/INS/GCP/454280/2010 GCP Inspectors Working Group (GCP IWG) Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical More information Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Electronic Copies of Electronic Records
Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Electronic Copies of Electronic Records Draft Guidance This guidance document is being distributed for comment purposes only. More information The Impact of 21 CFR Part 11 on Product Development
The Impact of 21 CFR Part 11 on Product Development Product development has become an increasingly critical factor in highly-regulated life sciences industries. Biotechnology, medical device, and pharmaceutical More information HESI: Fetal Imaging Workshop 21 CFR Part 11 Electronic Records & Signatures. Presented by: Jonathan S. Helfgott
HESI: Fetal Imaging Workshop 21 CFR Part 11 Electronic Records & Signatures Presented by: Jonathan S. Helfgott Director of Regulatory Affairs, Stage 2 Innovations Jonathan@stage2innovations.com Disclaimer More information Supplement to the Guidance for Electronic Data Capture in Clinical Trials
Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this More information Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application
Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research More information Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document More information Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug More information InfinityQS SPC Quality System & FDA s 21 CFR Part 11 Requirements
InfinityQS SPC Quality System & FDA s 21 CFR Part 11 Requirements www.infinityqs.com Copyright InfinityQS International Table of Contents Overview... FDA s 21 CFR Part 11 Requirements... PART 11 ELECTRONIC More information Nova Southeastern University Standard Operating Procedure for GCP. Title: Electronic Source Documents for Clinical Research Study Version # 1
Nova Southeastern University Standard Operating Procedure for GCP Title: Electronic Source Documents for Clinical Research Study Version # 1 SOP Number: OCR-RDM-006 Effective Date: August 2013 Page 1 of More information Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11)
Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11) The title 21 code of federal regulations part 11 deals with an institutions More information Medical Device Data Systems, Medical Image Storage Devices, and Medical Image
4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices; More information 1/30/2013. Agenda. Electronic Signatures/ Informed Consent
2013 UC Compliance & Audit Symposium Recordkeeping Matters: Part 11 Compliance Rachel Nosowsky ~ Acting Deputy General Counsel Rachel.Nosowsky@ucop.edu ~ (510) 987-9407 Agenda Electronic Signatures/Informed More information Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device industries
White Paper No 01 I December 2010 Implementation of 21 CFR Part 11 in the epmotion Software Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device More information Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation More information Computerized Systems Used in Medical Device Clinical Investigations
Computerized Systems Used in Medical Device Clinical Investigations Presented by Jonathan Helfgott Consumer Safety Officer Division of Bioresearch Monitoring Office of Compliance Center for Devices and More information 21 CFR PART 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES 21.11.2013. 21 CFR Part 11 Compliance PLA 2.1
21 CFR PART 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES Compliance of PLA 2.1 21.11.2013 21 CFR Part 11 Compliance PLA 2.1 SEC. 11.2 IMPLEMENTATION. (a) For records required to be maintained but not submitted More information Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry
Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments More information Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Maintenance of Electronic Records
Draft Guidance for Industry -- Not For Implementation Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Maintenance of Electronic Records Draft Guidance This guidance document More information InfoCenter Suite and the FDA s 21 CFR part 11 Electronic Records; Electronic Signatures
InfoCenter Suite and the FDA s 21 CFR part 11 Electronic Records; Electronic Signatures Overview One of the most popular applications of InfoCenter Suite is to help FDA regulated companies comply with More information Implement best practices by using FileMaker Pro 7 as the backbone of your 21 CFR 11 compliant system.
21 CRF 11 Electronic Records and Signatures Implement best practices by using FileMaker Pro 7 as the backbone of your 21 CFR 11 compliant system. By Todd Duell What does Title 21 of the Code of Federal More information A ChemoMetec A/S White Paper September 2013
NucleoCounter NC-3000, NucleoView NC-3000 Software and Code of Federal Regulation 21 Part 11; Electronic Records, Electronic Signatures (21 CFR Part 11) A ChemoMetec A/S White Paper September 2013 ChemoMetec More information Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International
Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing, More information Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding More information 21 CFR Part 11 Implementation Spectrum ES
21 CFR Part 11 Implementation Spectrum ES INFRARED SPECTROSCOPY T E C H N I C A L N O T E Introduction Compliance with 21 CFR Part 11 is mandatory for pharmaceutical companies and their suppliers to sell More information Guidance for Clinical Investigators, Industry, and FDA Staff Financial Disclosure by Clinical Investigators
Guidance for Clinical Investigators, Industry, and FDA Staff Financial Disclosure by Clinical Investigators U.S. Department of Health and Human Services Food and Drug Administration Office of Good Clinical More information Assessment of Vaisala Veriteq vlog Validation System Compliance to 21 CFR Part 11 Requirements
/ WHITE PAPER Assessment of Vaisala Veriteq vlog Validation System Compliance to 21 CFR Part 11 Requirements The 21 CFR Part 11 rule states that the FDA view is that the risks of falsification, misinterpretation, More information Compliance Matrix for 21 CFR Part 11: Electronic Records
Compliance Matrix for 21 CFR Part 11: Electronic Records Philip E. Plantz, PhD, Applications Manager David Kremer, Senior Software Engineer Application Note SL-AN-27 Revision A Provided By: Microtrac, More information 21 CFR Part 11 Compliance Using STATISTICA
21 CFR Part 11 Compliance Using STATISTICA Last Updated: April 2003 This document was updated to reflect the FDA s latest guidance (released February, 2003) and the withdrawal of previous guidance.! STATSOFT More information FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997)
www.qadata.co.za Introduction FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997) INITIAL REGULATION RELEASED High profile audit findings Industry complaints to wasting More information Guidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation More information Guidance for Industry Bar Code Label Requirements Questions and Answers
Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation More information DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics DRAFT GUIDANCE This guidance More information Remote Monitoring of Clinical Trials and EMRs
Remote Monitoring of Clinical Trials and EMRs Sandra SAM Sather, MS, BSN, CCRA, CCRC Vice-President Clinical Pathways LLC samsather@clinicalpathwaysresearch.com Lindsey Spangler, J.D. Associate Director, More information Full Compliance Contents
Full Compliance for and EU Annex 11 With the regulation support of Contents 1. Introduction 2 2. The regulations 2 3. FDA 3 Subpart B Electronic records 3 Subpart C Electronic Signatures 9 4. EU GMP Annex More information rsdm and 21 CFR Part 11
rsdm and 21 CFR Part 11 Meeting the 21 CFR Part 11 Burden without Overburdening The right solutions for smaller biopharma. Nothing more. Nothing less. Prepared by: Ken VanLuvanee www.virtualregulatorysolutions.com More information Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007
Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007 SIEMENS AG Industry Sector Industry Automation D-76181 Karlsruhe, Federal Republic of Germany E-mail: pharma.aud@siemens.com Fax: +49 More information Guidance for Industry
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data DRAFT GUIDANCE This guidance document is being More information Managing & Validating Research Data
Research Management Standard Operating Procedure ISOP-H02 VERSION / REVISION: 2.0 EFFECTIVE DATE: 01 03 12 REVIEW DATE: 01 03 14 AUTHOR(S): CONTROLLER(S): APPROVED BY: Information Officer; NBT Clinical More information Intland s Medical Template
Intland s Medical Template Traceability Browser Risk Management & FMEA Medical Wiki Supports compliance with IEC 62304, FDA Title 21 CFR Part 11, ISO 14971, IEC 60601 and more INTLAND codebeamer ALM is More information Electronic Records and Signatures: Compliance with Title 21 CFR Part 11 Requirements
Electronic Records and Signatures: Compliance with Title 21 CFR Part 11 Requirements Version 4.5. June 2015 Contents 1 Introduction... 3 2 Definitions (21 CFR Part 11: para 11.3)... 3 3 Administrative More information Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments More information Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims U.S. Department of Health and Human Services Food and Drug Administration Center for More information Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was More information 21 CFR Part 11 White Paper
21 CFR Part 11 White Paper Version V8.00 SR1 ProLeiT AG Einsteinstrasse 8, D-91074 Herzogenaurach, Germany Phone: +49 (0) 9132 777-0 Fax: +49 (0) 9132 777-150 E-Mail: info@proleit.com Internet: http://www.proleit.com More information Guidance for IRBs, Clinical Investigators, and Sponsors
Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval U.S. Department of Health and Human Services Food and Drug Administration Center for More information Guidance for Industry DRAFT GUIDANCE
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE More information Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and More information Guidance for Industry
Guidance for Industry Oversight of Clinical Investigations A Risk-Based Approach to Monitoring U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research More information Enabling SharePoint for 21 CFR Part 11 Compliance - Electronic Signature Use Case
Enabling SharePoint for 21 CFR Part 11 Compliance - Electronic Signature Use Case Sudeep Nambiar Technical Strategist www.linkedin.com/in/sudeepnambiar/ Thanks to our Sponsors! Platinum: Gold: Silver: More information Contains Nonbinding Recommendations
FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of More information Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of More information INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH
INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH Background and Company Performance Industry Challenges esource: Electronic Clinical Trial Solution Clinical trial sponsors and clinical research organizations More information Oracle WebCenter Content
Oracle WebCenter Content 21 CFR Part 11 Certification Kim Hutchings US Data Management Phone: 888-231-0816 Email: khutchings@usdatamanagement.com Introduction In May 2011, US Data Management (USDM) was More information DeltaV Capabilities for Electronic Records Management
January 2013 Page 1 DeltaV Capabilities for Electronic Records Management This paper describes DeltaV s integrated solution for meeting FDA 21CFR Part 11 requirements in process automation applications More information Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) More information Guidance for Industry
Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food More information Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration More information Data Management Unit Research Institute for Health Sciences, Chiang Mai University
Data Management Unit Research Institute for Health Sciences, Chiang Mai University Clinical Data Management is the process of handling data from clinical trials. The inherent goal of any clinical data More information Clinical database/ecrf validation: effective processes and procedures
TITOLO SLIDE Testo Slide Testo Slide Testo Slide Clinical database/ecrf validation: effective processes and procedures IV BIAS ANNUAL CONGRESS Padova September, 26 th 2012 PQE WORKSHOP: What's new in Computerized More information FDA 21 CFR Part 11 Electronic records and signatures solutions for the Life Sciences Industry
FDA 21 CFR Part 11 Electronic records and signatures solutions for the Life Sciences Industry The Rule 21 CFR Part 11 Handwritten signature means the scripted name or legal mark of an individual handwritten More information Guidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed More information White paper inforouter in the Life Sciences Industry: 21 CFR Part 11 Compliance
White paper inforouter in the Life Sciences Industry: 21 CFR Part 11 Compliance Overview of 21 CFR Part 11 The final version of the 21 CFR Part 11 regulation released by the FDA in 1997 provides a framework More information Compliance Response Edition 07/2009. SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures. simatic wincc DOKUMENTATION
Compliance Response Edition 07/2009 SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures simatic wincc DOKUMENTATION Compliance Response Electronic Records / Electronic Signatures More information DeltaV Capabilities for Electronic Records Management
September 2004 Page 1 An integrated solution for meeting FDA 21CFR Part 11 requirements in process automation applications using a configurable off-the-shelf (COTS) solution Emerson Process Management. More information Auditing Electronic data capture in clinical trials (EDC) The auditor s view
Auditing Electronic data capture in clinical trials (EDC) The auditor s view Where do auditors see such systems? Regulatory basic documents Key requirements Validation Auditfindings - Computer-Systems More information ROLE OF THE RESEARCH COORDINATOR
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Data Collection More information Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not More information POLICY ISSUES IN E-COMMERCE APPLICATIONS: ELECTRONIC RECORD AND SIGNATURE COMPLIANCE FDA 21 CFR 11 ALPHATRUST PRONTO ENTERPRISE PLATFORM
W H I T E P A P E R POLICY ISSUES IN E-COMMERCE APPLICATIONS: ELECTRONIC RECORD AND SIGNATURE COMPLIANCE FDA 21 CFR 11 ALPHATRUST PRONTO ENTERPRISE PLATFORM This white paper is written for senior executives More information HIMSS Electronic Health Record Definitional Model Version 1.0
HIMSS Electronic Health Record Definitional Model Version 1.0 Prepared by HIMSS Electronic Health Record Committee Thomas Handler, MD. Research Director, Gartner Rick Holtmeier, President, Berdy Systems More information Handling of electronic data in Clinical Trials part II - Practical Considerations and Implementation
Handling of electronic data in Clinical Trials part II - Practical Considerations and Implementation Anders Åkesson, Director Clinical Data Management Michael Seest, Associate Director, Development Compliance More information U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions More information Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation More information Contains Nonbinding Recommendations. Document issued on October 20, 2006
Guidance for Industry and FDA Staff Exemption from Certain Reporting and Recordkeeping Requirements for Television Receivers and Computer Monitors with Cathode Ray Tubes Document issued on October 20, More information FILEHOLD DOCUMENT MANAGEMENT SYSTEM 21 CFR PART 11 COMPLIANCE WHITE PAPER
FILEHOLD DOCUMENT MANAGEMENT SYSTEM 21 CFR PART 11 COMPLIANCE WHITE PAPER Copyright 2012 FileHold Systems Inc. All rights reserved. For further information about this manual or other FileHold Systems products, More information DATA MANAGEMENT IN CLINICAL TRIALS: GUIDELINES FOR RESEARCHERS
Reference Number: UHB 139 Version Number: 2 Date of Next Review: 14 Apr 2018 Previous Trust/LHB Reference Number: N/A DATA MANAGEMENT IN CLINICAL TRIALS: GUIDELINES FOR RESEARCHERS Introduction and Aim More information 21 CFR Part 11 Electronic Records & Signatures
Gap Analysis - Checklist 21 CFR Part 11 Electronic Records & Signatures his document is a proposal and starting point only. he type and extent of documentation depends on the process environment. he proposed More information DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed More information Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office More information Thermal Analysis. http://www.fda.gov. Subpart A General Provisions 11.1 Scope. 11.2 Implementation. 11.3 Definitions.
Thermal Analysis 21 CFR 11 Compliance 21 CFR Part 11 Electronic Records; Electronic Signatures General concept The U.S. Federal Food and Drug Administration (FDA) has issued regulations that provide criteria More information Update on Monitoring & Electronic Medical Records at UCSF
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Update on Monitoring & Electronic Medical Records January 10, 2012 at UCSF Danusia Filipowski, MD Director, More information Guidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and More information 2017 © DocPlayer.net Privacy Policy | Terms of Service | Feedback